AIM Vaccine Co., Ltd.

Clinical test application for ACW135 meningococcal polysaccharide vaccine (MCV4) as independently developed by AIM Vaccine has been accepted by Center for Drug Evaluation, NMPA for approval. This indicates the initiation of formal approval of MCV4 for clinical tests. Presently, there are only three foreign enterprises engaged in production of MCV4 worldwide, and no product has been approved for listing in China. AIM Vaccine comes into the frontier in China in terms of R&D of such key product. By using polysaccharide protein coupling technology, MCV4 independently developed by AIM Vaccine has realized grouping of common pathogenic meningococci serums as represented by A, C, W135 and Y for covalent bonding with carrier protein CRM197. As compared with MAV vaccines on sales in the market, it has more extensive protection scope and effect. Epidemic cerebrospinal meningitis (known as ECM) is a serious infectious disease caused by neisseria meningitides. The incidence rate among children under 5 years old, especially infants under 12 months old is the highest in China. The program as issued by WHO to defeat meningitis in by 2030 advocates “elimination of meningitis as an epidemic disease to reduce the numbers cases and death toll of meningitis available for prevention with the help of vaccines by 80%”. 34 countries worldwide have incorporated combined vaccines for 4v ECM into national immune planning. As indicated by AIM, MCV4 is expected to induce immune response among children under 2 years old. Such product will make up deficiencies to meningococcal vaccines for infants under 2 years old in China once approved for launch.

By September 9, AIM Vaccine had completed low-dosage and medium-dosage recruitment of adult patients for mRNA COVID-19 vaccine at phase-1 clinical laboratory of Shulan (Hangzhou) Hospital. According to results of preliminary test, the vaccine has manifested a high safety and tolerance after inoculation. In addition to aforesaid mRNA OCVID-19 vaccine, AIM inactivated COVID-19 vaccine is also making a smooth progress during phase-1 clinical test, which has completed recruitment of all testees (low, medium and high dosage groups) and low-dosage old testees. By September 9, such vaccine had manifested a high safety and tolerance after inoculation according to results of preliminary test. AIM Vaccine is a comprehensive vaccine corporation with its own mRNA technical platform, of which products have entered the stage of clinical test. Its COVID-19 vaccine product combinations under development are in 4 technical routes, including mRNA COVID-19 vaccine under development based on 2nd generation of technologies, inactivated COVID-19 vaccine under development, recombinant protein COVID-19 vaccine under development as well as broad-spectrum COVID-19 vaccine under development based on adenovirus vectors. AIM Vaccine is making efforts to accelerate R&D and production of COVID-19 vaccine products. Recently, the company has established its bio-safety protection Level 3 (P3) workshop of inactivated COVID-19 vaccine at Ningbo Free Trade Zone with anticipated annual output up to 500 million dosages. Furthermore, a national advanced bio-safety laboratory (P3) is also under accelerated construction at the same plant. In the future, AIM Vaccine will further enhance intimate cooperation with all parties to provide COVID-19 vaccine products of higher safety and efficiency against COVID-19 epidemics.

On the morning of September 3, Zhou Ting, Board Chairman and CEO of AIM Vaccine Co., Ltd attended “One-day for Beijing” and anniversary celebration of “Two-zone” construction at 2021 China International Fair for Trade in Services under invitation, and participated in the signing ceremony for “Two-zone” project. PRC head office and phase-1 project innovative vaccine industrialization base of AIM Vaccine have been listed as important contracted projects for “two-zone” construction in Beijing with introduced investments through strict screening. It is one of 37 key projects completed contract conclusion with Beijing Economic-Technological Development Area t the site on the current day. This year marks inauguration of the 14th Five-Year Plan. Beijing is making efforts to promote the construction of “two zones”, namely National Integrated Demonstration Zone for Greater Openness in the Service Sector and a the Pilot Free Trade Zone at a higher level. This gives priority to scientific innovation, openness in service sector and cyber economic features in an attempt to construct a high-level platform for BTH Coordinated Development, and promote formation of a new pattern of reform and opening-up at a higher level. “Two-zone” construction serves as a rare opportunity and major responsibility endowed by the Party Central Committee. In the past year, “Two-zone” construction was incorporated into one of “five divisions” for Beijing to accommodate with new pattern of development, resulting in numerous practical cases for promotion nation wide. Furthermore, some new policies have been implemented in together with some landmark projects, which have accomplished periodical achievements. AIM Vaccine feels high excitement and great mission and responsibility for being enlisted for important contracted projects for “two-zone” construction in Beijing with introduced investments. AIM Vaccine will profoundly study the spirit of important address as made by Xi Jinping, General Secretary of the Central Committee of the Communist Party of China at Global Trade in Services Summit of China International Fair for Trade in Services to take a lead in innovation, and consciously participated in construction of new high land for further opening-up of the capital. We will further improve scientific innovation level under the leadership and support of Beijing Municipal Party Committee and Government to engage in vaccine R&D, and take production of innovative vaccine products as our own responsibility. We will manage to become an important link of “sophisticated industrial development blue map” of Beijing Economic-Technological Development Area, and make use of high technologies to support “two-zone” construction, and make our contributions to construction of Beijing into a scientific innovation center with global impact.